NCT00250419View on ClinicalTrials.gov

V930 First in Man (FIM) Study (V930-002)(COMPLETED)

PHASE1CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Cancers Expressing HER-2 and/or CEA

Interventions

BIOLOGICAL

V930

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00250419 - V930 First in Man (FIM) Study (V930-002)(COMPLETED) | Biotech Hunter | Biotech Hunter